objectives To evaluate a paediatric treatment-support intervention for home-based treatment of HIV infection or tuberculous meningitis (TBM).
Introduction
In 2016, South Africa was home to 0.9% of all children (age 0-14) globally [1] and accounted for 15.2% of the global human immunodeficiency virus (HIV) infected children [2] and 5.6% of the global tuberculosis (TB) incidence in children [3, 4] . South Africa has more people on antiretroviral treatment (ART) than any other country in the world [5] . Tuberculous meningitis (TBM) is the most severe form of TB and frequently occurs in early childhood [6] . In the Western Cape of South Africa, 14.9% of all culture confirmed TB cases in children (<13 years) at two major referral hospitals had TBM [7] . Although South Africa has adopted strategic plans to address the HIV and TB pandemic [8] , there is inadequate capacity to deliver critical health-care interventions [9] .
Successful treatment of any condition requires high levels of adherence [10, 11] . Poor treatment adherence is common, contributing to substantial worsening of disease, death, drug resistance and increased health-care costs [12] [13] [14] [15] . The overall number of HIV-related deaths declined by 60.7% between 2006 and 2016, however, the number of HIV-related deaths in 10-19 year-olds increased by 77.1% in the same period [2] . Non-adherence was an important contributing factor [15] . Depending on measure and definition, ART adherence in South African children ranged between 20.5% and 89.1% [16] . Paediatric adherence to TB treatment ranged between 27.6% and 82.6% depending on regimen and duration of treatment [17] .
Since 2010, paediatric ART service delivery has been decentralised to the primary healthcare level [18] , which is based on nurse-driven service through clinics [19] . Inhospital treatment is the gold standard for children with neuro-tuberculosis due to complexity of care and serious consequences of non-adherence to anti-TB treatment [20] . Long-term hospitalisation can negatively affect the child and family [21] . Short intensified treatment at home, under certain conditions, is a viable alternative to in-hospital treatment of children with drug-susceptible TBM [22, 23] .
To address adherence and support successful treatment outcome, a qualitative study was conducted involving home-based paediatric TBM treatment. This study identified difficulties with administering medication and the caregiver's limited understanding of disease and medication as barriers to adherence. The idea to support medication intake by calendar monitoring was highly valued [24] . The findings of this study were translated into a non-digital treatment-support intervention in collaboration with diverse stakeholders involved in realising effective treatment (patients, caregivers, nurses, medical doctors, pharmacists, social workers and school teachers). The intervention was adapted for paediatric HIV medicine use in collaboration with stakeholders involved with HIV care when healthcare providers expressed an interest in its use. The diversity of treatment regimens, duration of treatment and effect of the condition on daily functioning between HIV infection and TBM provided for two diverse populations to evaluate this intervention.
Few non-digital low-cost treatment-support interventions have been reported [25] . There exists a paucity of data on the efficacy of interventions in resource-constrained environments, highlighting the urgent need for prospectively designed, randomised controlled evaluations of interventions to improve paediatric adherence to ART [26] and TB treatment [11] .
Adherence is a dynamic process [11] not only affected by health system challenges [27] but also by clinical, child, caregiver and socio-economic characteristics [28, 29] . In order to implement treatment-support interventions at scale, it is important to explore their effect on adherence. The aim of this study was to determine the impact of this affordable, cultural friendly, non-digital treatment-support intervention in two endemic, potentially life threatening childhood diseases, namely HIV infection and TBM.
Methods

Study design and setting
A randomised controlled study was conducted including children with HIV infection and TBM in the Western Cape of South Africa with the aim to determine the impact of a non-digital treatment-support intervention ( Figure 1 ).
The first group consisted of caregivers and their HIVinfected children (aged 2-14 years) on antiretroviral therapy (ART) at TC Newman clinic (HIV group) and was included between September 2012 and September 2013. This out-patient ART clinic was visited monthly; every 2 months when appropriate for selected cases. The clinic provided HIV counsellors to support adherence and facilitate the HIV disclosure process. The paediatric ART regimen is characterised by life-long, twice daily treatment with a combination of three medicines [16] .
The second group consisted of caregivers and their children with TBM (age 0-14 years) who were initially stabilised at Tygerberg Hospital and were recruited between August 2011 and October 2013 upon discharge on home-based treatment (TBM group). The out-patient clinic was visited monthly and provided a dedicated programme nurse to coordinate follow-up appointments and support adherence. A social worker was involved with the screening for suitability for home-based therapy [23] , application for social grants and was available to families on home-based treatment where required. Different to WHO standard guidelines for TBM treatment of 12 months [30] , the local standard was a short-intensified 6-months, once-daily treatment regimen with a combination of four medicines (isoniazid, rifampicin, pyrazinamide and ethionamide) [23] .
We aimed to include 200 children in the HIV group and 100 children in the TBM group based on power of 0.80 and alpha of 0.05. Participants were assigned to control (local standard care) or intervention groups (local standard care plus non-digital treatment-support intervention) using block randomisation upon their first visit to the HIV clinic and upon discharge onto TBM homebased treatment. Randomisation in the TBM group was stratified by age (<5 years and ≥ 5 years) as TBM frequently occurs in early childhood. In both settings (HIV and TBM), the intervention was provided at each monthly clinic visit.
The study was approved by the Stellenbosch University's Health Research Ethics Committee (N11/11/329 and N11/03/061) and hospital management in accordance with Provincial Research Policy (58/2012 and 40/ 2009). Written consent was obtained from all caregivers and assent from children older than 7 years with normal cognitive function.
Non-digital treatment-support intervention
The central framework used to develop the intervention was the health belief model [31] . The qualitative study used an interview guide based on the caregivers' perceived susceptibility to and severity of their child's condition, and the perceived benefits and barriers of adhering to their child's treatment [24] . The findings were translated into the intervention (Figure 2 ) which combined education (information brochure), adherence reinforcement (sticker puzzle), and adherence monitoring (calendar). The information brochure was developed to support caregivers to understand the condition (HIV is not mentioned) and the treatment regimen (side effects, forgetting, vomiting, when to give, food, timing and storage). The sticker-chart was developed to support the child; when the medication is taken, a sticker is put on a puzzle chart for 30 days revealing a different image each month (different for boys and girls). The HIV group (bi-daily regimen) was designed with two stickers indicated with a sun and moon, the TBM group (once daily regimen) consisted of one sticker per day.
The calendar part of the intervention is filled out by the caregiver, monitoring adherence and difficulties for both caregiver/child and healthcare provider. The intervention is explained by the counsellor (HIV group) or programme nurse (TBM group) and discussed with the healthcare provider at each visit.
Study procedures
Interviews using structured questionnaires were conducted with caregivers in the paediatric out-patient department prior to physician consults and supplemented with medical record information. Child-, caregiver-, clinical-, and socio-economic characteristics were collected. WHO clinical staging of HIV disease in children was applied [32] and TBM stage classified based on the Glasgow Coma Scale [23] . Socio-Economic Status (SES)-index was calculated using 21 questions from the Census 2011 [33] including number of people per household, type of dwelling, drinking water, toilet facilities, sharing of facilities, fuel for cooking heating and lighting, material of floor and walls, room sharing and assets (radio, TV, fridge, computer, landline, cell-phone, care bicycle, motorcycle, donkey and sheep). A higher mean index-score (%) indicated better SES. Within the HIV group, all measures were recorded at baseline (T0) and at 6-months follow-up (T6). TBM group measures were recorded at baseline (T0) and at 3-months follow-up (T3). Adherence by self-report in the TBM group was measured at first (T1) and third follow-up visit (T3). 
Adherence measures
In both groups, self-reported adherence and difficulties experienced with administering medication in the last three and 30 days was recorded using the validated Paediatric AIDS clinical trials group (PACTG) adherence modules [34, 35] . Adherence was defined as no missed dosages within the time period indicated. In addition, using this questionnaire, we identified difficulties experienced in the past 30 days with administering medication.
In the HIV group, adherence was additionally measured by pill counts and calculated using the number of pills taken (dispensed minus returned) as a percentage of medication prescribed. Pill counts were obtained from medical records. Pill counts between 95-105% were defined as adherent.
In the TBM group, adherence was additionally measured with drug assays. A urine colour test for rifampicin was performed; orange/red was positive for rifampicin and defined adherent, yellow was negative and defined nonadherent [36] . IsoScreen (GFC Diagnostics Limited, Oxfordshire, UK, Arkansas method) urine testing was performed to identify the presence of isoniazid (INH) metabolites; dark blue/purple colour change indicated positivity for INH (adherent); green indicated INH intake but not in the last 36 h, and no colour change implied nonadherence [36, 37] . Saliva production was enhanced by application of a 20 mg citric acid cotton swab to the buccal mucosa and collection occurred using a Salivette â (SARSTEDT BV, Etten-Leur, The Netherlands) pipet. The Salivette â was centrifuged at 1000 g for 2 min, clear saliva supernatant was stored in polypropylene tubes at À80°C within 2 h after collection.
The samples were transported on dry ice to the laboratory at the Department of Pharmacy, Radboud University Medical Center in Nijmegen, The Netherlands for bioanalysis. Salivary concentrations of pyrazinamide (mg/L) were determined with a validated high-performance liquid chromatography [38] . Adherence was defined when the concentration measured within the range of 0.585-58.5 mg/L.
Effect measures
During interviews, children's health-related quality of life (HRQoL) was measured using the validated Paediatric quality of life inventory TM (PedsQL TM ) 4.0 generic core scale questionnaires. The parent-proxy report is combined with the child self-report (>5 years) and measures physical, emotional, social and school functioning. The infant scales (1-24 months) also included physical symptoms and cognitive functioning [39] [40] [41] .
Family impact was defined as the impact of paediatric chronic health conditions on caregiver and family and was measured with the PedsQL TM 2.0 family impact module questionnaires. This module includes parent functioning (physical, emotional, social cognitive, communication and worry) and family functioning (daily activities and family relationships) [42] .
HRQoL and family functioning items were measured on a 5-point Likert scale which was converted to a percentage score. A higher score (0-100%) indicated better HRQoL and better overall family functioning [43] . A score below or over the median score was used to compare groups.
Based on caregiver interview, healthcare provider report and medical files, we categorised disclosure status as non-disclosure (the child is unaware of their condition and its effect on the body), partial disclosure (the child is aware of their condition without actually naming HIV) and full disclosure (the child is made aware of their condition which is named as HIV) [44] .
Analyses
All analyses were done using SPSS statistics version 25 (IBM â corporation, South Africa). To compare intervention and control groups at one time-point, we present chi-squared test P-values unless otherwise specified (Fisher's exact P-value when cell size below 5). Significance was measured at P < 0.05. To explore change over time within one group we present the McNemar test P-value and significance was measured at P < 0.10.
Ethical approval
The study was approved by the Stellenbosch University's Health Research Ethics Committee (N11/11/329 and N11/03/061) and hospital management in accordance with Provincial Research Policy (58/2012 and 40/ 2009).
Results
HIV group
At the HIV clinic, there were 238 active patients on ART aged 2-14. One caregiver declined participation because HIV infection was not disclosed to the child (13 years) yet, and 42 patients visited on a date when research staff was not present. At baseline, 195 children were included.
Children were 8.0 years (mean; median 8.3, IQR 5.7-10.2, range 2.1-12.9 years) and 113 (57.9%) were girls. Most caregivers were female (n = 180, 92.3%), home language was Xhosa (n = 130, 66.7%) and households consisted of five people (mean) ( Table 1) . For five households with two children in the study, only the child enrolled first was considered for SES analyses (n = 190). At baseline, the intervention group was similar to the control group for all of the child-, caregiver-, clinical-and socio-economic measures presented (P > 0.05). The puzzle and calendar were presented at the appointments and discussed with the programme nurse and occasionally with the clinician (returned and used 82 of 93, 88.2%).
Adherence (all measures) was similar for children using the intervention compared to controls at baseline and there was no difference between groups at follow-up. Over time, adherence did not change in the intervention group. Over time, the proportion of children who were adherent increased in the control group (by 7.7% for 3-day recall, P = 0.092; and by 9.1% for 30-day recall, P = 0.096). Adherence measured by pill count was similar at follow-up for children using the intervention and controls and did not change over time (Table 2) .
At baseline, all effect measures were similar for both the intervention and control groups (P > 0.05). At follow-up, more children using the intervention had good healthrelated quality of life compared to controls (19.9% difference between groups, P = 0.009). Between baseline and follow-up, the proportion of children using the intervention with a good health-related quality of life increased by 11.8% (P = 0.089), there was no change over time for controls (Table 2) . Number needed to treat (use the intervention) in order to benefit was five for health-related quality of life and eight for family functioning.
At follow-up, the percentage of caregivers reporting problems with administering medication was similar for children using the intervention compared to controls (P > 0.05). The proportion of caregivers reporting problems did not change over time in the intervention group but declined in the control group by 13.1% (P = 0.043). Problems included that the caregiver forgot to administer medication, was away from home, ran out and did not refill drugs, and drugs had bad palatability.
At follow-up, disclosure (full/partial) of HIV status to the child was similar for children using the intervention compared to controls (P > 0.05). This proportion increased over time for children using the intervention by 13.4% (P > 0.001) and for controls by 6.2% (P = 0.031) ( Table 2 ). Disclosure conversion from non-disclosed to disclosed (partial/full) occurred for 13 (17.6%) children in the intervention group and 6 (7.9%) children in the control group (P = 0.075).
Tuberculous meningitis group
During the inclusion period, 63 children aged 0-14 years were admitted on home-based treatment for TBM. At recruitment, 12 caregivers declined participation, eight children were missed (timing of discharge changed), and 43 children and their caregivers were included. Children were 5.5 years (mean; median 4.1, IQR 2.6-8.2, range 0.8-13.2 years) and 21 (48.8%) were girls. Most caregivers were female (n = 41, 95.3%), home-language was Afrikaans (n = 25, 58.1%) and households consisted of 6 people (mean) ( Table 1) . At baseline, the intervention group was not different from the control group for any of the child-, caregiver-, clinical-or socio-economic measures presented (P > 0.05).
During routine monthly clinic visits (standard care) within the follow-up period, four children were readmitted (multi-drug resistant TB, non-adherence, not attending appointments, deterioration of condition) and two caregivers chose to discontinue participation (timeconsuming and social reasons). These six children were excluded from 3-months follow-up analyses. The puzzle and calendar were presented at the appointments and discussed with the programme nurse and occasionally with the clinician (returned and used 16 of 19, 84.2%).
At baseline, adherence (all measures) was similar for children using the intervention compared to controls (P > 0.05). The proportion of children being adherent according to self-report (3 and 30-day recall) remained high (100%) over time in both groups. Although intervention and controls were similar at follow-up for all drug assay measures for adherence (isoniazid, rifampicin and pyrazinamide) (P > 0.05), the change over time was different between groups. Between baseline and followup, adherence for isoniazid did not change (remained 100%) for children using the intervention, the decline of 23.1% in the control group was not significant. Adherence for rifampicin declined over time in the intervention group by 37.5% (P = 0.031); the decline of 23.0% in the control group was not significant. Adherence for pyrazinamide remained high over time for children using the intervention and for controls (Table 3) .
At baseline, all effect measures were similar for the intervention and control group (P > 0.05). Between baseline and follow-up, the proportion children with good health-related quality of life remained similar in the intervention group whereas the proportion of children with good health-related quality of life scores decreased in the control group by 29.4% (P = 0.063). At follow-up, more children using the intervention had a good family impact score compared to the control group (P = 0.040) ( Table 3) . Number needed to treat (use the intervention) in order to benefit was five for health-related quality of life and three for family functioning. Problems reported with administering medication included that the caregivers worried about side effects, ran out and did not refill, and there was too much medication to give, children refusing medication and bad palatability of drugs. Table 2 HIV group -Difference between intervention and control group, and change over time within groups Presenting proportion of children who were adherent, proportion of children with above median HRQoL or family impact scores, proportion caregivers who reported one or more problems administering medication, and proportion of children who received disclosure. HRQoL, health-related quality of life, Chi-square P-value for intervention compared to control, at one point in time, McNemar Pvalue for follow-up (T6) compared to baseline (T0), change over time within one group. *Significant P < 0.10, **Significant P < 0.05.
Discussion
This study evaluated a low-cost, cultural friendly treatment-support intervention in two endemic, potentially life-threatening infectious diseases conditions (HIV and TBM) in the Western Cape of South Africa. Use of the intervention supported good health-related quality of life and family functioning, but did not lead to an increase in adherence in these two study populations. Self-reported adherence in the HIV group remained similar over time for children using the intervention whereas self-reported adherence increased in the control group; adherence measured by pill count remained similar over time in both groups. Self-reporting tends to overestimate adherence, whereas drug-assays and pill counts are more reliable and accurate measures of adherence [29] . The increase in self-reported adherence could be explained by social desirability bias, where using the intervention enabled a more accurate estimation of adherence by caregivers in the HIV group.
The high levels of adherence in the TBM group for both intervention and controls could be explained by the rigorous evaluation for home-based treatment eligibility prior to participation [22, 23] , and the appreciation of caregivers for the importance of adherence which is reinforced by the distressing period preceding diagnosis [24] . All children (100%) using the intervention remained adherent measured by drug assay for isoniazid and pyrazinamide. Future research could further explore the effect of the intervention on maintaining good adherence in populations with high baseline levels such as TBM. Low levels of adherence for rifampicin could be explained by poor palatability which is strongly correlated with non-adherence in children [45] . In addition, children might be misclassified as non-adherent measured by rifampicin assay [36] as the duration of the Presenting proportion of children who were adherent, proportion of children with above median HRQoL or family impact scores, proportion caregivers who reported one or more problems administering medication. *Significant P < 0.10, **Significant P < 0.05, †Fish-er's exact P-value for intervention compared to control at one point in time baseline or follow-up) for cell-size <5, ‡Baseline T1. RMP, rifampicin; INH, isoniazid; PZA, pyrazinamide; HRQoL, health-related quality of life. Chi-square P-value for intervention compared to control at one point in time, McNemar P-value for follow-up compared to baseline, change over time within one group.
urine colouration by rifampicin is short and may be absent altogether [37] . Adherence can be jeopardised by social issues within a family (poor physical or mental health and limited social support) [46, 47] . Availability of emotional and practical life support is critical for adherence [11] . More children using the intervention had good health-related quality of life compared to controls in the HIV group, and remained a high proportion of children with good healthrelated quality of life in the TBM group. Family functioning as measured by the proportion of children with good family impact scores was higher at follow-up for children using the intervention compared to the control group (TBM group). The intervention may enable a favourable social structure at home beneficial to the emotional and social functioning.
A decrease in caregivers' report of problems experienced when administering medication could be expected as families get used to the treatment regimen over time. Where the use of the intervention could have encouraged caregivers to continue expressing difficulties with healthcare providers, the decline identified in the HIV control group could possibly be explained by caregivers providing a more socially desirable representation of their problems.
An important finding was that disclosure of HIV status to the child increased over time. National guidelines recommend all children from age of 3 years to be prepared for disclosure [44] . Disclosure is the first step for children transitioning into adolescents and young adults who successfully manage their own HIV care [48] . Increased disclosure over time is to be expected, as the responsibility for treatment will gradually be shifting from caregiver to (shared with) the child [39] . The intervention can serve as a tool to commence the disclosure process and open communication between child, caregiver and healthcare provider.
ART adherence interventions in Sub-Saharan setting exist (such as text messages and reminder devices, treatment supporters, directly observed therapy, education and counselling, food supplements, and different healthsystem approaches to ART delivery) [25] , however, welldesigned evaluations of interventions to improve paediatric adherence to ART are limited [26] . In addition, there is lack of rigorous experimental research on the effects of interventions to promote adherence to TB treatment [11] especially in a home-based setting.
Adherence to medication is a dynamic process [11] and requires routinisation of anticipatory behaviour, which is deeply embedded in, and shaped by complex social and material context. Where medication itself has effect through a physical mechanism, an intervention (designed to improve medication adherence) relies on the mechanism of suggestion to shape anticipatory behaviour [49] . Our findings imply that this suggestion was insufficient to for altering the range of elements that shape adherence. To get a better understanding of the way the intervention works and affects adherence, a randomised effectiveness study could be supplemented with a qualitative study on how children and their families in a specific context make use of the intervention.
Small sample size and missing data in the TBM group are limitations to our study. Adherence in the HIV group by self-report and pill-counts include all ART prescribed. In the TBM group, self-reports included all medicines prescribed, however, adherence to ethionamide was not measured by drug-assay. Ethionamide frequently causes vomiting [50] which can affect adherence. In addition, the HRQoL and family functioning index-scores do not follow a normal distribution and were included as dichotomous outcome (below or over median score) which could provide for potential bias.
The time-frame of this evaluation (follow-up at 6-months in the HIV group and 3-months in the TBM group) is possibly too short to establish health behaviour change (long-term adherence). Although the majority returned and used the puzzle/calendar part of the intervention, the study did not measure if the brochure was read which possibly affected the outcomes measured and is a limitation of the study.
Conclusion
The low-cost, culturally friendly treatment-support intervention had beneficial effects on health-related quality of life, family functioning and facilitated the disclosure process of HIV status to the child. Treatment adherence was not significantly affected in both the HIV and TBM groups. The intervention resulted in an increased caregiver reporting of medication non-adherence and caregiver reporting of difficulties they experienced with administering medication.
